z-logo
open-access-imgOpen Access
Depression and prostate cancer risk: A Mendelian randomization study
Author(s) -
Chen Xiong,
Kong Jianqiu,
Diao Xiayao,
Cai Jiahao,
Zheng Junjiong,
Xie Weibin,
Qin Haide,
Huang Jian,
Lin Tianxin
Publication year - 2020
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.3493
Subject(s) - mendelian randomization , depression (economics) , medicine , major depressive disorder , prostate cancer , single nucleotide polymorphism , oncology , cancer , genetics , biology , genetic variants , genotype , gene , amygdala , macroeconomics , economics
Background The association between depression and prostate carcinogenesis has been reported in observational studies but the causality from depression on prostate cancer (PCa) remained unknown. We aimed to assess the causal effect of depression on PCa using the two‐sample Mendelian randomization (MR) method. Methods Two sets of genetics instruments were used for analysis, derived from publicly available genetic summary data. One was 44 single‐nucleotide polymorphisms (SNPs) robustly associated with major depressive disorder (MDD) and the other was two SNPs related with depressive status as ever depressed for a whole week. Inverse‐variance weighted method, weighted median method, MR‐Egger regression, MR Pleiotropy RESidual Sum, and Outlier test were used for MR analyses. Results No evidence for an effect of MDD on PCa risk was found in inverse‐variance weighted (OR: 1.12, 95% CI: 0.97‐1.30, p  = 0.135), MR‐Egger (OR 0.89, 95% CI: 0.29‐2.68, p  = 0.833), and weighted median (OR: 1.08, 95% CI: 0.92‐1.27, p  = 0.350). Also, no strong evidence for an effect of depressive status on PCa incidence was found using the inverse‐variance weighted method (OR 0.72, 95% CI: 0.35‐1.47, p  = 0.364). Conclusions The large MR analysis indicated that depression may not be causally associated with a risk of PCa.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here